Advertisement

Breast Cancer Research and Treatment

, Volume 34, Issue 1, pp 71–76 | Cite as

Parity is associated with axillary nodal involvement in operable breast cancer

  • Richard K. Orr
  • Kathleen M. Fraher
Report

Summary

Introduction. Although multiparous women have a decreased incidence of breast cancer, several series have observed that multiparous women have a higher risk of axillary nodal metastases and diminished survival.

Methods. To study this hypothesis in greater detail, this study analyzed data from 223 consecutive women with clinically operable (T1-3, N0-1, M0) breast cancer, all of whom had undergone axillary node dissection (AND) by one surgeon (83 mastectomy/AND, 140 lumpectomy/AND). The number of pregnancies and other hormonally related factors were recorded. Results were compared to pathologic data (node status, tumor size, estrogen and progesterone receptors).

Results. Seventy-eight patients (35.0%) had positive axillary nodes. Increasing parity was associated with an increased likelihood of positive nodes (Odds ratio 1.22 (95% CI: 1.04–1.42), p = 0.012) as was increasing tumor size (Odds ratio 1.31 (1.07–1.59), p = 0.007). The effect of parity was independent of tumor size, age, or hormone receptors.

Conclusions. In this series, which includes only operatively staged patients, increasing parity is associated with nodal positivity. This effect is of a magnitude similar to that of increasing tumor size, and confirms observations from other studies. Information regarding parity may be useful for prognostic purposes, as well as providing insights into basic breast cancer biology.

Key words

axillary lymphadenectomy breast neoplasms parity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kampert JB, Whittemore AS, Paffenbarger RS Jr: Combined effect of childbearing, menstrual events, and body size on age-specific breast cancer risk. Am J Epi 128: 962–979, 1988Google Scholar
  2. 2.
    Palmer MK, Lythgoe JP, Smith A: Prognostic factors in breast cancer. Br J Surg 69: 697–698, 1982Google Scholar
  3. 3.
    Papatestas AE, Mulvihill M, Josi C, Ioannovich J, Lesnick G, Aufses AH Jr: Parity and prognosis in breast cancer. Cancer 45: 191–194, 1980Google Scholar
  4. 4.
    Black MM, Hankey BF, Barclay THC: Parity as a prognostic factor in young breast cancer patients. J Natl Cancer Inst 70: 27–30, 1983Google Scholar
  5. 5.
    Mohle-Boetani JC, Grosser S, Whittemore AS, Malec M, Kampert JB, Paffenbarger RS Jr: Body size, reproductive factors, and breast cancer survival. Prev Med 17: 634–642, 1988Google Scholar
  6. 6.
    Lees AW, Jenkins HJ, May CL, Cherian G, Lam EWH, Hanson J: Risk factors and 10-year breast cancer survival in northern Alberta. Breast Cancer Res Treat 13: 143–151, 1989Google Scholar
  7. 7.
    Mason BH, Holdaway IM, Stewart AW, Neave LM, Kay RG: Season of tumour detection influences factors predicting survival of patients with breast cancer. Breast Cancer Res Treat 15: 27–37, 1990Google Scholar
  8. 8.
    Lehrer S, Levine E, Savoretti P, Cropley J, Botstein C, Song HK et al.: Past pregnancy is associated with axillary node involvement in women with breast cancer. Cancer 69: 981–983, 1992Google Scholar
  9. 9.
    Danforth DN Jr, Lippman ME: Surgical treatment of breast cancer. In: Lippman ME, Lichter AS, Danforth DN Jr (eds) Diagnosis and Management of Breast Cancer. Philadelphia, WB Saunders, 1988, pp. 95–154Google Scholar
  10. 10.
    Borland International, 1800 Green Hills Road, Scotts Valley, CA 95067Google Scholar
  11. 11.
    SPSS, Inc, 444 N Michigan Ave, Chicago, IL. 60611Google Scholar
  12. 12.
    Hosmer DW, Lemeshow S: Applied Logistic Regression New York, Wiley-Interscience, 1989Google Scholar
  13. 13.
    Ruder AM, Lubin F, Wax Y, Geier A, Alfundary E, Chetrit A: Estrogen and progesterone receptors in breast cancer patients: Epidemiologic characteristics and survival differences. Cancer 64: 196–202, 1989Google Scholar
  14. 14.
    Cooper JA, Rohan TE, Cant ELM, Horsfall DJ, Tilley WD: Risk factors for breast cancer by oestrogen receptor status: a population based case-control study. Brit J Cancer 59: 119–125, 1989Google Scholar
  15. 15.
    G.I.V.I.O. (Interdisciplinary Group for Cancer Care Evaluation) Italy. Breast cancer estrogen and progesterone receptors: Associations with patients' clinical and epidemiologic characteristics. Tumori 77: 472–478, 1991Google Scholar
  16. 16.
    Yu MC, Gerkins VR, Henderson BE, Brown JB, Pike MC: Elevated levels of prolactin in nulliparous women. Br J Cancer 43: 826–831, 1981Google Scholar
  17. 17.
    Bernstein K, Pike MC, Ross RK, Judd HL, Brown JB, Henderson BE: Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. J Natl Cancer Inst 74: 741–745, 1985Google Scholar
  18. 18.
    Russo J, Tay LK, Russo IH: Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 2: 5–73, 1982Google Scholar
  19. 19.
    Woods KL, Smith SR, Morrison JM: ‘Parity and breast cancer: evidence of a dual effect. Brit Med J 281: 419–421, 1980Google Scholar
  20. 20.
    Janerich DT, Hoff MB: Evidence for a crossover in breast cancer risk factors. Am J Epi 116: 737–742, 1982Google Scholar
  21. 21.
    Bruzzi P, Negri E, La Vecchia C, Decarli A, Palli D, Parazzini F, Del Turco MR: Short term increase in risk of breast cancer after full term pregnancy. Brit Med J 297: 1096–1098, 1988Google Scholar
  22. 22.
    Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW: Obesity at diagnosis of breast cancer influences duration of disease-free survival. Ann Int Med 116: 26–32, 1992Google Scholar
  23. 23.
    Sellers TA, Kushi LH, Potter JD, Kaye SA, Nelson CL, McGovern PG, Folsom AR: Effect of family history, bodyfat distribution, and reproductive factors on the risk of postmenopausal breast cancer. N Engl J Med 326: 1323–1329, 1992Google Scholar
  24. 24.
    Ingram DM, Nottage EM, Roberts AN: Prolactin and breast cancer risk. Med J Australia 153: 469–473, 1990Google Scholar
  25. 25.
    Deckers PJ: Axillary dissection in breast cancer: When, why, how much, and for how long? Another operation soon to be extinct? J Surg Oncol 48: 217–219, 1991Google Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Richard K. Orr
    • 1
  • Kathleen M. Fraher
    • 1
  1. 1.The Fallon Clinic Breast Center, and the Section of Surgical OncologyThe Fallon Clinic and St. Vincent HospitalWorcesterUSA

Personalised recommendations